BostonGene

What BostonGene does

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene’s unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene’s mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies

Name

BostonGene

Legal name

BostonGene Corporation

Website

http://www.bostongene.com/

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

501–1,000 employees

Short description

BostonGene is a biomedical software company for advanced patient analysis and personalized therapy in the fight against cancer.

Ownership category

akta.pro rank

Product category

Precision Oncology Analytics

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (513210)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Precision oncology analytics
• Multiomic molecular profiling
• AI-driven biomarker discovery
• Clinical genomic sequencing
• Immune profiling services

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Biopharma Partnerships and Platform Services: BostonGene generates revenue through strategic partnerships with biopharmaceutical organizations, providing AI-powered analytics platforms for drug development, patient selection, and clinical trial optimization. Engagements typically begin as focused pilots and expand into broader platform integration.
2. Clinical Laboratory Testing Services: BostonGene operates through its CLIA-certified, CAP-accredited laboratory providing molecular profiling services including whole exome sequencing, transcriptome sequencing, liquid biopsy, and immunoprofiling for healthcare providers and biopharma partners.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

BostonGene provides a cloud-based AI-driven multimodal analytics platform that integrates whole exome sequencing, whole transcriptome sequencing, liquid biopsy, immune profiling, spatial proteomics, and digital pathology to analyze tumors, microenvironments, and host immunity. The company sells its BostonGene Tumor Portrait® test and related clinical assays to healthcare providers and oncologists, and offers AI-powered target identification, biomarker discovery, clinical trial support, and drug repurposing modules to biopharmaceutical partners via a subscription/enterprise model.

Product overview

BostonGene offers a cloud-based AI platform that integrates multiple molecular and immune profiling techniques to comprehensively analyze tumors, microenvironments, and host immunity for precision oncology. The platform combines whole exome sequencing, whole transcriptome sequencing, liquid biopsy (ctDNA/cfRNA), single-cell RNA sequencing, flow cytometry, spatial proteomics, and digital pathology into a unified system. For biopharma clients, the platform provides target identification, biomarker discovery, clinical trial support, drug repurposing, and unmet need identification modules. For healthcare providers, BostonGene offers the BostonGene Tumor Portrait test, Immune System Profiling, IHC testing, and Unknown Primary testing. The company operates its own CLIA-certified, CAP-accredited laboratory and partners with leading biopharmaceutical organizations and academic institutions.

Differentiator

Problem solved

Functional benefit

Brands

• Kassandra™: AI-based tool that reconstructs tumor microenvironment from gene expression data
• BostonGene Tumor Portrait® test
• PAM50(BG)

Products and services

• BostonGene Tumor Portrait® test Integrated solution providing a holistic 360° overview for each cancer patient, identifying key biomarkers for response to various therapies in patients with advanced solid tumors. Uses DNA whole exome and RNA transcriptome sequencing for comprehensive molecular profiling.
• Immune System Profiling Blood-based immune profiling providing a snapshot of the patient's immune health by identification of hundreds of different cell types from a single tube of blood, using flow cytometry and AI-based models.
• Immunohistochemistry (IHC) test AI-based testing for clinically actionable biomarkers such as PD-L1 and MMR with automated workflow applicable to various markers including nuclear, cytoplasm/membrane, and complex membrane markers.
• Unknown Primary test Identifies the tumor's origin using DNA and RNA sequencing to help guide treatment decisions for patients with cancers of unknown primary.
• Whole Transcriptome Sequencing (WTS / RNA-seq) Sequencing of nearly 20,000 genes enabling precise identification of gene fusions, expression levels, and gene expression signatures in a CLIA/CAP environment, with tumor microenvironment analysis, TCR/BCR repertoire, and HLA haplotyping.
• Whole Exome Sequencing (WES) Sequencing of nearly 20,000 genes providing uniform coverage across 99.7% of coding regions, enabling unbiased detection of genetic variants (SNVs, indels, CNAs, LOH, TMB, MSI) in a CLIA/CAP environment.
• Liquid Biopsy (ctDNA and cfRNA sequencing) Minimally invasive blood-based tumor profiling enabling identification of biomarkers and monitoring of treatment response at both DNA and RNA levels via ctDNA and cfRNA assays.
• Single-cell RNA sequencing High-resolution analysis of individual transcriptomes from thousands of cells within a single sample, revealing cell-specific transcriptional changes and identifying rare, functionally significant cell populations.
• Flow Cytometry State-of-the-art flow cytometry including analytical flow cytometry and cell sorting to assess immune system status from standard blood samples. Supports basic immunoprofiling (10 panels, >800 cell populations) and advanced immunoprofiling.
• Spatial Proteomics End-to-end multiplex immunofluorescence (MxIF) pipeline offering comprehensive overview of tissue architecture and cell-cell interactions by detecting up to 60 protein markers from a single slide with single-cell resolution.
• Digital Pathology AI-based digital pathology platform that identifies distinct characteristics of tumor and microenvironment, reducing need for manual analysis. Supports H&E analysis, IHC detection, and multiplex immunofluorescence from whole-slide images.
• Biomarker Discovery Platform AI-powered platform for biomarker discovery and validation, integrating multiomic data including genomics, transcriptomics, and immune profiling to improve patient selection, optimize trial design, and accelerate oncology drug development.
• Target Analysis Solution Leverages proprietary genomic and transcriptomic databases to pinpoint the most promising cancer types for drug candidates and identify novel therapeutic targets.
• Drug Repurposing Solutions AI-driven end-to-end drug repurposing platform discovering beneficial drug-disease matches to maximize the potential of existing drug portfolios.

Quantifiable outcome

• Identified actionable RNA findings in all enrolled patients in FEASY study
• +2 more outcomes

Named customers12 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability7 records

Feature11 records

Partnerships

Twelve partnerships are on record, tiered core, minor and flagship.

• Kyoto UniversitycoreStrategic or Co-development Partner · 22 July 2026Strategic research partnership supporting multicenter Phase II clinical trial evaluating combined immune checkpoint inhibitors (ICI) and photodynamic therapy (PDT) for advanced gastrointestinal cancers. BostonGene applies its multimodal AI analytics platform to identify molecular signatures and immune-response patterns associated with therapeutic response.
• Hokkaido UniversitycoreStrategic or Co-development Partner · 11 May 2026Expanded multi-year strategic research collaboration to advance precision oncology in Japan. BostonGene conducts next-generation sequencing and integrated analysis of DNA, RNA, and immune profiles from tumor samples across more than 20 cancer types to identify patient-specific disease drivers and guide therapeutic decision-making.
• ImmunoGenesiscoreStrategic or Co-development Partner · 14 April 2026Strategic partnership to accelerate clinical development of IMGS-001, a cytotoxic immune checkpoint inhibitor targeting both PD-L1 and PD-L2. BostonGene applies its AI-driven multiomic and spatial biology platform to perform molecular characterization and identify patients most likely to respond to treatment.
• UnileverminorStrategic or Co-development Partner · 3 March 2026Strategic collaboration to apply advanced AI and multiomics approaches to scientific exploration and long-term innovation in consumer products. The partnership extends BostonGene's AI foundation model beyond oncology into consumer-focused science.
• Daiichi SankyoflagshipStrategic or Co-development Partner · 17 February 2026Strategic collaboration to integrate AI-driven translational intelligence into Daiichi Sankyo's antibody drug conjugate (ADC) development program. BostonGene generates digital twin representations from hundreds of thousands of multiomic and histopathologic patient profiles to enable precise patient selection and optimize clinical trial design.
• AstraZenecaflagshipStrategic or Co-development Partner · 6 January 2026Strategic collaboration to advance oncology drug development using BostonGene's multimodal AI platform. AstraZeneca applies BostonGene's omnimodal analytics to deliver predictive insights on patient-level safety and efficacy outcomes in early clinical trials, accelerating development timelines and reducing risk across its oncology portfolio.
• TakedacoreStrategic or Co-development Partner · 1 August 2024Partnership to leverage BostonGene's AI-powered multiomics platform in select early-stage clinical trials. BostonGene performs sophisticated multiomic analytics including flow cytometry, RNA-seq, and proteomics data to enhance trial design, improve indication selection, and identify biomarker signatures for response and toxicity.
• MD Anderson Cancer CentercoreStrategic or Co-development PartnerCollaborative research in FEASY study published in Cancer Discovery demonstrating that RNA-based multiomic analysis identified new therapeutic targets for antibody-drug conjugates in patients with advanced solid tumors who previously had no actionable results from DNA testing alone.
• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerCollaborative research demonstrating integrated molecular profiling for refining risk assessment, predicting CAR-T therapy resistance, and identifying biomarkers for patient selection in blood cancers. Partnership on multi-omic profiling to identify genomic subtypes associated with differential outcomes after CAR-T therapy.
• Weill Cornell MedicinecoreStrategic or Co-development PartnerCollaborative research on AI-driven multiomics platforms for blood cancer treatment optimization including CAR-T therapy outcomes and lymphoma research.
• Friends of Cancer ResearchcoreStrategic or Co-development PartnerCollaboration on landmark blinded, multi-vendor HER2 benchmarking study published in Modern Pathology. BostonGene's AI foundation model received independent validation achieving high agreement rates across 10 AI models for assessing HER2 expression in breast cancer.
• UT MD Anderson Cancer CentercoreStrategic or Co-development PartnerCollaborative research on integrated transcriptomic and immune profiling for chronic lymphocytic leukemia treatment, pancreatic cancer KRAS/MTAP analysis, and multiple myeloma risk stratification research.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Tempus AI: Tempus AI is the most direct competitor, offering a multimodal AI platform that integrates genomic, transcriptomic, imaging, and clinical data for biopharma R&D and clinical oncology decision support — overlapping with BostonGene across both biopharma partnerships and clinical diagnostics offerings.
• Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx) used widely for therapy selection and biopharma trial enrollment — directly overlapping with BostonGene's Tumor Portrait and biopharma patient stratification offerings.
• Caris Life Sciences: Caris offers MI Profile and Caris Assure for multiomic tumor profiling plus biopharma services including Caris Discovery — directly comparable to BostonGene's combined lab services and biopharma platform strategy in precision oncology.
• Personalis: Personalis provides ImmunoID Next and NeXT Personal liquid biopsy tests and biopharma services for tumor molecular profiling — overlapping with BostonGene's WES/WTS, liquid biopsy, and biopharma analytics offerings.
• PathAI: PathAI builds AI-powered pathology and biomarker platforms deployed with biopharma for clinical trial analytics and companion diagnostics — directly comparable to BostonGene's digital pathology and biopharma AI platform modules.
• Owkin: Owkin operates an AI platform for patient stratification, biomarker discovery, and trial optimization serving biopharma — directly overlapping with BostonGene's biopharma target identification, biomarker discovery, and clinical trial support modules.
• Paige AI: Paige builds AI-based digital pathology models including Paige Prostate (FDA-authorized) for cancer diagnosis and biopharma applications — directly comparable to BostonGene's AI-based digital pathology, IHC detection, and HER2 benchmarking work.

Broad incumbents

• Guardant Health: Guardant Health is a liquid biopsy leader (Guardant360, Reveal) with a broader commercial footprint and FDA-approved diagnostics — overlapping with BostonGene's liquid biopsy (cfDNA/cfRNA) services but with established payer coverage and a public market scale BostonGene does not yet have.

Emerging players

• Natera: Natera's Signatera MRD test and oncology offerings compete in molecular monitoring and treatment response — partial overlap with BostonGene's liquid biopsy and treatment-response monitoring services, primarily in the clinical rather than biopharma channel.
• Recursion Pharmaceuticals: Recursion applies AI foundation models across multiomic and imaging data for drug discovery, with biopharma partnerships — adjacent to BostonGene's biopharma AI platform and foundation-model approach, though Recursion focuses more on therapeutic discovery rather than trial analytics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/bostongenesys
• YouTubeyoutube.com/channel/UCvu9tWwr-xyI1O9QM314NCw
• Facebookfacebook.com/BostonGeneCorp
• LinkedInlinkedin.com/company/bostongene

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BostonGene